|
Q3 FY2025
As of Sep 30, 2025
|
Q2 FY2025
As of Jun 30, 2025
|
Q1 FY2025
As of Mar 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q3 FY2024
As of Sep 30, 2024
|
Q2 FY2024
As of Jun 30, 2024
|
Q1 FY2024
As of Mar 31, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
Q3 FY2023
As of Sep 30, 2023
|
Q2 FY2023
As of Jun 30, 2023
|
Q1 FY2023
As of Mar 31, 2023
|
Q4 FY2022
As of Dec 31, 2022
|
Q3 FY2022
As of Sep 30, 2022
|
Q2 FY2022
As of Jun 30, 2022
|
Q1 FY2022
As of Mar 31, 2022
|
Q4 FY2021
As of Dec 31, 2021
|
Q3 FY2021
As of Sep 30, 2021
|
Q2 FY2021
As of Jun 30, 2021
|
Q1 FY2021
As of Mar 31, 2021
|
Q4 FY2020
As of Dec 31, 2020
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||||||||||||
| Real estate properties | ||||||||||||||||||||
| Net investment in sales-type lease | ||||||||||||||||||||
| Less: accumulated depreciation | ||||||||||||||||||||
| Real estate assets held for sale, net | ||||||||||||||||||||
| Real estate properties, net | ||||||||||||||||||||
| Cash | ||||||||||||||||||||
| Cash held in escrow | ||||||||||||||||||||
| Restricted cash | ||||||||||||||||||||
| Investment in unconsolidated joint ventures | ||||||||||||||||||||
| Deferred lease intangibles, net | ||||||||||||||||||||
| Other assets | ||||||||||||||||||||
| Interest rate swaps | ||||||||||||||||||||
| Forward contract asset | ||||||||||||||||||||
| Total assets | ||||||||||||||||||||
| Liabilities, Redeemable Non-controlling Interest and Equity | ||||||||||||||||||||
| Liabilities: | ||||||||||||||||||||
| Secured debt, net | ||||||||||||||||||||
| Unsecured debt, net | ||||||||||||||||||||
| Borrowings under line of credit | ||||||||||||||||||||
| Accounts payable, accrued expenses and other liabilities | ||||||||||||||||||||
| Real estate liabilities held for sale, net | ||||||||||||||||||||
| Warrant liability | ||||||||||||||||||||
| Embedded derivative liability - Series C Preferred Units | ||||||||||||||||||||
| Deferred lease intangibles, net | ||||||||||||||||||||
| Financing lease liability | ||||||||||||||||||||
| Interest rate swaps | ||||||||||||||||||||
| Total liabilities | ||||||||||||||||||||
| Preferred stock | ||||||||||||||||||||
| Series A Preferred Stock | ||||||||||||||||||||
| Redeemable non-controlling interest - Series C Preferred Units, 500,000 units authorized, (aggregate liquidation preference of $186,587 and $81,985 at September 30, 2025 and December 31, 2024, respectively) | ||||||||||||||||||||
| Equity: | ||||||||||||||||||||
| Common stock, $0.01 par value: 900,000,000 shares authorized; 44,551,164 and 45,389,186 shares issued and outstanding at September 30, 2025 and December 31, 2024, respectively | ||||||||||||||||||||
| Additional paid in capital | ||||||||||||||||||||
| Accumulated deficit | ||||||||||||||||||||
| Accumulated other comprehensive income | ||||||||||||||||||||
| Total stockholders' equity | ||||||||||||||||||||
| Non-controlling interest | ||||||||||||||||||||
| Total equity | ||||||||||||||||||||
| Total liabilities, redeemable non-controlling interest and equity | ||||||||||||||||||||
Loading...
